Primary intraosseous non-Hodgkin lymphoma in the mandible is uncommon, representing about 0.6% of all extranodal lymphomas. We present the case of a 51-year-old male with a 4-month complaint of mandibular swelling and paresthesia, which had been previously submitted to an unsuccessful periodontal treatment. The intra-oral evaluation showed an extensive swelling with teeth mobility in the right mandible body. The panoramic radiography and computed tomography images showed an extensive osteolytic lesion. An incisional biopsy was performed and the histopathological and immunohistochemical analysis established the diagnosis of diffuse large B-cell lymphoma. The treatment included six cycles of chemotherapy with complete remission. The patient is under the seventh month of follow-up with no evidence of relapse. Although uncommon in the oral cavity, lymphoma should be considered in the differential diagnosis.
Keywords
Head and Neck Neoplasms, Lymphoma, Large B-Cell, Diffuse, Oral Medicine
PazokiA, JansisyanontP, OrdRA. Primary non-Hodgkin’s lymphoma of the jaws: report of 4 cases and review of the literature. J Oral Maxillofac Surg. 2003;61(1):112-7. [https://doi.org/10.1053/joms.2003.50018]. [PMID:12524617]
OkahataR, ShimamotoH, MarutaniK, et al. Diffuse large B-cell lymphoma of the mandible with periosteal reaction: A case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(2):e228-32. [https://doi.org/10.1016/j.oooo.2013.12.002]. [PMID:24439924]
JessriM, AbdulMajeedAA, MatiasMA, FarahCS. A case of primary diffuse large B-cell non-Hodgkin’s lymphoma misdiagnosed as chronic periapical periodontitis. Aust Dent J. 2013;58(2):250-5. [https://doi.org/10.1111/adj.12056]. [PMID:23713648]
DonaduzziLC, ReinheimerA, SilvaMAR, et al. Primary diffuse large B cell lymphoma mimicking hyperplastic reactive lesion (lymphoma of the oral cavity). Case Rep Pathol. 2018;2018:1-9. [https://doi.org/10.1155/2018/2981689]. [PMID:29552368]
BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [https://doi.org/10.3322/caac.21492]. [PMID:30207593]
JainP, FayadLE, RosenwaldA, YoungKH, O’BrienS. Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol. 2013;88(9):798-802. [https://doi.org/10.1002/ajh.23467]. [PMID:23695956]
HaradaS, SuzukiR, UehiraK, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5-with CD10+groups may constitute clinically relevant subtypes. Leukemia. 1999;13(9):1441-7. [https://doi.org/10.1038/sj.leu.2401487]. [PMID:10482997]
LinP, DickasonTJ, FayadLE, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer. 2012;118(6):1566-73. [https://doi.org/10.1002/cncr.26433]. [PMID:21882178]
ThakralB, MedeirosLJ, DesaiP, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017;98(4):415-21. [https://doi.org/10.1111/ejh.12847]. [PMID:28039906]
MiyazakiK, YamaguchiM, SuzukiR, et al. CD5-positive diffuse large B-cell lymphoma: A retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601-7. [https://doi.org/10.1093/annonc/mdq627]. [PMID:21199885]
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email